Skip to main content Accessibility help
  • Print publication year: 2019
  • Online publication date: December 2018

15 - Pharmacological Treatments for Obsessive-Compulsive and Related Disorders: A Transdiagnostic Perspective

from Section 2 - Practical Aspects of Obsessive-Compulsive Disorder

Related content

Powered by UNSILO
1.Haro, JM, Ayuso-Mateos, JL, Bitter, I, et al. ROAMER: roadmap for mental health research in Europe. Int J Methods Psychiatr Res. 2014;23(S1):114.
2.Insel, T, Cuthbert, B, Garvey, M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748751.
3.Hollander, E, Braun, A, Simeon, D. Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. Depress Anxiety. 2008;25(4):317329.
4.Stein, DJ, Kogan, CS, Atmaca, M, et al. The classification of obsessive-compulsive and related disorders in the ICD-11. J Affect Disord. 2016;190:663674.
5.Fineberg, NA, Menchon, JM, Zohar, J, Veltman, DJ. Compulsivity: a new trans-diagnostic research domain for the Roadmap for Mental Health Research in Europe (ROAMER) and Research Domain Criteria (RDoC) initiatives. Eur Neuropsychopharmacol. 2016;26(5):797799.
6.Hollander, E, Doernberg, E, Shavitt, R, et al. The cost and impact of compulsivity: a research perspective. Eur Neuropsychopharmacol. 2016;26(5):800809.
7.Marras, A, Fineberg, N, Pallanti, S. Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. CNS Spectr. 2016;21(4):324333.
8.Fineberg, NA, Baldwin, DS, Menchon, JM, et al. Manifesto for a European research network into obsessive-compulsive and related disorders. Eur Neuropsychopharmacol. 2013;23(7):561568.
9.Lochner, C, Fineberg, NA, Zohar, J, et al. Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Compr Psychiatry. 2014;55(7):15131519.
10.De Vries, FE, Cath, DC, Hoogendoorn, AW, et al. Tic-related versus tic-free obsessive-compulsive disorder: clinical picture and 2-year natural course. J Clin Psychiatry. 2016;77(10):e1240e1247.
11.Kaur, S, Wikramanayake, M, Kolli, S, et al. Autistic spectrum disorder in adults with obsessive compulsive disorder: results from a UK survey. Eur Neuropsychopharmacol. 2016;26(5):886887.
12.Darrow, SM, Hirschtritt, ME, Davis, LK, et al. Identification of two heritable cross-disorder endophenotypes for Tourette syndrome. Am J Psychiatry. 2016;174(4):387396.
13.Dell’Osso, B, Benatti, B, Buoli, M, et al. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). Eur Neuropsychopharmacol. 2013;23(8):865871.
14.Fineberg, NA, Hengartner, MP, Bergbaum, C, Gale, T, Rössler, W, Angst, J. Remission of obsessive-compulsive disorders and syndromes; evidence from a prospective community cohort study over thirty years. Int J Psychiatry Clin Pract. 2013;17(3):179187.
15.Fineberg, NA, Gale, TM. Evidence-based pharmacotherapy of obsessive compulsive disorder. Int J Neuropsychopharmacol. 2005;8(1):107129.
16.Fineberg, NA, Brown, A, Reghunandanan, S, Pampaloni, I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012;15(8):11731191.
17.Stein, DJ, Fineberg, N, Reghunandanan, S. Obsessive-Compulsive and Related Disorders, 2nd ed. Oxford University Press; 2015.
18.Hollander, E, Stein, DJ, Fineberg, NA, Marteau, F, Legault, M. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry. 2010;71(6):784792.
19.Stein, DJ, Andersen, EW, Tonnoir, B, Fineberg, N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23(4):701711.
20.Tenney, NH, Denys, DA, van Megen, HJ, Glas, G, Westenberg, HG. Effect of a pharmacological intervention on quality of life in patients with obsessive–compulsive disorder. Int Clin Psychopharmacol. 2003;18(1):2933.
21.Soomro, GM, Altman, D, Rajagopal, S, Oakley-Browne, M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;1:CD001765.
22.McGuire, JF, Piacentini, J, Lewin, AB, Brennan, EA, Murphy, TK, Storch, EA. A meta-analysis of cognitive behavior therapy and medication for child obsessive-compulsive disorder: moderators of treatment efficacy, response, and remission. Depress Anxiety. 2015;32(8):580593.
23.Skapinakis, P, Caldwell, DM, Hollingworth, W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3(8):730739.
24.Foa, EB, Steketee, G, Kozak, MJ, Dugger, D. Effects of imipramine on depression and obsessive-compulsive symptoms. Psychiatry Res. 1987;21(2):123136.
25.Volavka, J, Neziroglu, F, Yaryura-Tobias, JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. 1985;14(1):8593.
26.Insel, TR, Murphy, DL, Cohen, RM, Alterman, I, Kilts, C, Linnoila, M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40(6):605612.
27.Jenike, MA, Baer, L, Minichiello, WE, Rauch, SL, Buttolph, ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997;154(9):12611264.
28.Ananth, J, Pecknold, JC, Van Den Steen, N, Engelsmann, F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol. 1981;5(3):257262.
29.Thoren, P, Asberg, M, Cronholm, B, Jornestedt, L, Traskman, L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry. 1980;37(11):12811285.
30.McDougle, CJ, Price, LH, Goodman, WK, Charney, DS, Heninger, GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991;11(3):175184.
31.Pigott, TA, L’Heureux, F, Hill, JL, Bihari, K, Bernstein, SE, Murphy, DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12(1):1118.
32.Stein, DJ, Hollander, E, Mullen, LS, DeCaria, CM, Liebowitz, MR. Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. Hum Psychopharmacol Clin. 1992;7(6):389395.
33.Hewlett, WA, Vinogradov, S, Agras, WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12(6):420430.
34.Hollander, E, Kaplan, A, Stahl, SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003;4(1):3034.
35.Crockett, BA, Churchill, E, Davidson, JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry. 2004;16(3):127132.
36.Fineberg, NA, Hengartner, MP, Bergbaum, C, Gale, T, Rössler, W, Angst, J. Lifetime comorbidity of obsessive-compulsive disorder and sub-threshold obsessive-compulsive symptomatology in the community: impact, prevalence, socio-demographic and clinical characteristics. Int J Psychiatry Clin Pract. 2013;17(3):188196.
37.Hoehn-Saric, R, Ninan, P, Black, DW, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000;57(1):7682.
38.Bloch, MH, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, MB, Leckman, JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622632.
39.Abramovitch, A, Dar, R, Mittelman, A, Schweiger A. Don’t judge a book by its cover: ADHD-like symptoms in obsessive compulsive disorder. J Obsessive-Compuls Relat Disord. 2013;2(1):5361.
40.King, J, Dowling, N, Leow, F. Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report. Australas Psychiatry. 2016;25(2):178180.
41.Taormina, SP, Galloway, MP, Rosenberg, DR. Treatment efficacy of combined sertraline and guanfacine in comorbid obsessive–compulsive disorder and attention deficit/hyperactivity disorder: two case studies. J Dev Behav Pediatr. 2016;37(6):491495.
42.The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48(8):730738.
43.De Veaugh-Geiss, J, Landau, P, Katz, R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatr Ann. 1989; 19(2):9799.
44.Issaria, Y, Jakubovski, E, Bartley, CA, Pittenger, C, Bloch, MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry. 2016;77(5):e605e611.
45.Da Conceição Costa, DL, Shavitt, RG, Cesar, RC, et al. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. J Psychiatr Res. 2013;47(11):17001707.
46.Rasmussen, S, Hackett, E, Duboff, E, et al. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12(6):309316.
47.Koran, LM, Sallee, FR, Pallanti, S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997;154(3):396401.
48.Bloch, MH, McGuire, J, Landeros-Weisenberger, A, Leckman, JF, Pittenger, C. Meta-analysis of the dose–response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850855.
49.Baldwin, DS, Anderson, IM, Nutt, DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567596.
50.Baldwin, DS, Anderson, IM, Nutt, DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403439.
51.American Psychiatric Association. Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association; 2007.
52.Andrews, G. Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry. 2001;178(3):192194.
53.Grady, TA, Pigott, TA, L’Heureux, F, Hill, JL, Bernstein, SE, Murphy, DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150(5):819821.
54.Sugarman, MA, Kirsch, I, Huppert, JD. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis. J Affect Disord. 2017;218:217226.
55.De la Fuente-Fernández, R, Ruth, TJ, Sossi, V, Schulzer, M, Calne, DB, Stoessl, AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science. 2001;293(5532):11641166.
56.Enck, P, Benedetti, F, Schedlowski, M. New insights into the placebo and nocebo responses. Neuron. 2008;59(2):195206.
57.Scott, DJ, Stohler, CS, Egnatuk, CM, Wang, H, Koeppe, RA, Zubieta, JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65(2):220231.
58.Figee, M, de Koning, P, Klaassen, S, et al. Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. Biol Psychiatry. 2014;75(8):647652.
59.Fineberg, NA, Chamberlain, SR, Goudriaan, AE, et al. New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity. CNS Spectr. 2014;19(1):6989.
60.Baumgarten, HG, Grozdanovic, Z. Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry Suppl. 1998;(35):1320.
61.El Mansari, M, Blier, P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuro-psychopharmacol Biol Psychiatry. 2006;30(3):362373.
62.Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):17351740.
63.Skoog, G, Skoog, I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1999;56(2):121127.
64.Eisen, JL, Sibrava, NJ, Boisseau, CL, et al. Five-year course of obsessive-compulsive disorder: predictors of remission and relapse. J Clin Psychiatry. 2013;74(3):233239.
65.Fineberg, NA, Pampaloni, I, Pallanti, S, Ipser, J, Stein, DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder. Int Clin Psychopharmacol. 2007;22(6):313322.
66.Fineberg, NA, Reghunandanan, S, Brown, A, Pampaloni, I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry. 2013;47(2):121141.
67.Santana, L, Versiani, M, Mendlowicz, MV, Fontenelle, LF. Predictors of adherence among patients with obsessive-compulsive disorder undergoing naturalistic pharmacotherapy. J Clin Psychopharmacol. 2010;30(1):8688.
68.Menchón, JM, van Ameringen, M, Dell’Osso, B, et al. Standards of care for obsessive-compulsive disorder centres. Int J Psychiatry Clin Pract. 2016;20(3):204208.
69.Micali, N, Heyman, I, Perez, M, et al. Long-term outcomes of obsessive-compulsive disorder: follow-up of 142 children and adolescents. Br J Psychiatry. 2010;197(2):128134.
70.Reddy, YC, Alur, AM, Manjunath, S, Kandavel, T, Math, SB. Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(3):267272.
71.Garcia, AM, Sapyta, JJ, Moore, PS, et al. Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am Acad Child Adolesc Psychiatry. 2010;49(10):10241033.
72.Storch, EA, Milsom, VA, Merlo, LJ, et al. Insight in pediatric obsessive-compulsive disorder: associations with clinical presentation. Psychiatry Res. 2008;160(2):212220.
73.Storch, EA, Merlo, LJ, Larson, MJ, et al. Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(5):583592.
74.Baer, L, Jenike, MA. Personality disorders in obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15(4):803812.
75.Baer, L, Jenike, MA, Black, DW, Treece, C, Rosenfeld, R, Greist, J. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(11):862866.
76.Jenike, MA, Baer, L, Minichiello, WE, Schwartz, CE, Carey, RJ Jr. Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry. 1986;143(4):530532.
77.Erzegovesi, S, Cavallini, MC, Cavedini, P, Diaferia, G, Locatelli, M, Bellodi, L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol. 2001;21(5):488492.
78.McDougle, CJ, Goodman, WK, Leckman, JF, Barr, LC, Heninger, GR, Price, LH. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993;13(5):354358.
79.Hazari, N, Narayanaswamy, JC, Arumugham, SS. Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. Expert Rev Neurother. 2016;16(10):11751191.
80.Leckman, JF, Rauch, SL, Mataix-Cols, D. Symptom dimensions in obsessive-compulsive disorder: implications for the DSM-V. CNS Spectr. 2007;12(5):376387, 400.
81.Bloch, MH, Craiglow, BG, Landeros-Weisenberger, A, et al. Predictors of early adult outcomes in pediatric-onset obsessive-compulsive disorder. Pediatrics. 2009; 124(4):10851093.
82.Conelea, CA, Walther, MR, Freeman, JB, et al. Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II. J Am Acad Child Adolesc Psychiatry. 2014;53(12):13081316.
83.Højgaard, DR, Skarphedinsson, G, Nissen, JB, Hybel, KA, Ivarsson, T, Thomsen, PH. Pediatric obsessive-compulsive disorder with tic symptoms: clinical presentation and treatment outcome. Eur Child Adolesc Psychiatry. 2017; 26(6):681689.
84.Bloch, MH, Bartley, CA, Zipperer, L, et al. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. Mol Psychiatry. 2014;19(9):10251030.
85.Mataix-Cols, D, Rauch, SL, Manzo, PA, Jenike, MA, Baer, L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999;156(9):14091416.
86.Landeros-Weisenberger, A, Bloch, MH, Kelmendi, B, et al. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010;121(1–2):175179.
87.Koran, LM, Simpson, HB. Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association; 2013.
88.Ninan, PT, Koran, LM, Kiev, A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006;67(1):1522.
89.Fineberg, NA, Reghunandanan, S, Simpson, HB, et al. Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res. 2015;227(1):114125.
90.Khalsa, SS, Schiffman, JE, Bystritsky, A. Treatment-resistant OCD: options beyond first-line medications. Curr Psychiatr. 2011;10(11):45.
91.Connor, KM, Payne, VM, Gadde, KM, Zhang, W, Davidson, JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005; 66(1):4951.
92.Ercan, ES, Ardic, UA, Ercan, E, Yuce, D, Durak, S. A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2015;25(7):580584.
93.Skapinakis, P, Papatheodorou, T, Mavreas, V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17(2):7993.
94.Vulink, NC, Denys, D, Fluitman, SB, Meinardi, JC, Westenberg, HG. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70(7):1001.
95.Carey, PD, Lochner, C, Kidd, M, Van Ameringen, M, Stein, DJ, Denys, D. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive–compulsive disorder: is response to treatment predictable? Int Clin Psychopharmacol. 2012;27(6):321325. Available at doi:10.1097/YIC.0b013e3283576881 (accessed April 19, 2017).
96.Dold, M, Aigner, M, Lanzenberger, R, Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557574.
97.Veale, D, Miles, S, Smallcombe, N, Ghezai, H, Goldacre, B, Hodsoll, J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14(1):317.
98.Ducasse, D, Boyer, L, Michel, P, et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology. 2014;231(18):37653770.
99.Marinova, Z, Chuang, DM, Fineberg, N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15(7):977995.
100.Insel, TR, Hamilton, JA, Guttmacher, LB, Murphy, DL. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology. 1983;80(3):231235.
101.Joffe, RT, Swinson, RP, Levitt, AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol. 1991;11(4):237241.
102.Rodriguez, CI, Kegeles, LS, Levinson, A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):24752483.
103.Koran, LM, Gamel, NN, Choung, HW, Smith, EH, Aboujaoude, EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515520.
104.Ghaleiha, A, Entezari, N, Modabbernia, A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47(2):175180.
105.Haghighi, M, Jahangard, L, Mohammad-Beigi, H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology. 2013;228(4):633640.
106.Grant, PJ, Joseph, LA, Farmer, CA, et al. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive–compulsive disorder. Neuropsychopharmacology. 2014;39(6):14531459.
107.Pittenger, C, Bloch, MH, Wasylink, S, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(8):10751084.
108.Emamzadehfard, S, Kamaloo, A, Paydary, K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016;70(8):332341.
109.Bruno, A, Micò, U, Pandolfo, G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012;26(11):14561462.
110.Khalkhali, M, Aram, S, Zarrabi, H, Kafie, M, Heidarzadeh, A. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry. 2016;11(2):104114.
111.Afshar, H, Roohafza, H, Mohammad-Beigi, H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797803.
112.Sarris, J, Oliver, G, Camfield, DA, et al. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29(9):801809.
113.Paydary, K, Akamaloo, A, Ahmadipour, A, Pishgar, F, Emamzadehfard, S, Akhondzadeh, S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016; 41(2):214219.
114.Costa, DLC, Diniz, JB, Requena, G, et al. Randomized, double-blind, placebo-controlled trial of n-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(7):e766e773.
115.Koran, LM, Aboujaoude, E, Bullock, KD, Franz, B, Gamel, N, Elliott, M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353359.
116.Heidari, M, Zarei, M, Hosseini, SM, et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder. Int Clin Psychopharmacol. 2014;29(6):344350.
117.Soltani, F, Sayyah, M, Feizy, F, Malayeri, A, Siahpoosh, A, Motlagh, I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol Clin. 2010;25(6):509513.
118.Askari, N, Moin, M, Sanati, M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomised, double-blind, placebo-controlled trial. CNS Drugs. 2012;26(10):883892.
119.Wu, K, Hanna, GL, Rosenberg, DR, Arnold, PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive–compulsive disorder. Pharmacol Biochem Behav. 2012;100(4):726735.
120.Ting, JT, Feng, G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics. 2008;2:6275.
121.Pittenger, C, Bloch, MH, Williams, K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132(3):314332.
122.Pauls, DL, Abramovitch, A, Rauch, SL, Geller, DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014;15(6):410424.
123.Rosenberg, DR, Mirza, Y, Russell, A, Tang, J, Smith, JM, Banerjee, SP, Bhandari, R, Rose, M, Ivey, J, Boyd, C, Moore, GJ. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1146–53.
124.Rosenberg, DR, MacMaster, FP, Keshavan, MS, Fitzgerald, KD, Stewart, CM, Moore, GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000; 39(9):10961103.
125.Kavirajan, H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf. 2009;8(1):89109.
126.Aboujaoude, E, Barry, JJ, Gamel, N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009;29(1):5155.
127.Bakhla, AK, Verma, V, Soren, S, Sarkhel, S, Chaudhury, S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J. 2013;22(2):149152.
128.Feusner, JD, Kerwin, L, Saxena, S, Bystritsky, A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42(1):8193.
129.Niciu, MJ, Henter, ID, Luckenbaugh, DA, Zarate, CA Jr, Charney, DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol. 2014;54:119139.
130.Price, RB, Nock, MK, Charney, DS, Mathew, SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522526.
131.Goodman, WK, Price, LH, Rasmussen, SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):10061011.
132.Bloch, MH, Wasylink, S, Landeros-Weisenberger, A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72(11):964970.
133.Pittenger, C, Coric, V, Banasr, M, Bloch, M, Krystal, JH, Sanacora, G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008;22(9):761786.
134.Coric, V, Taskiran, S, Pittenger, C, et al. Riluzole augmentation in treatment-resistant obsessive–compulsive disorder: an open-label trial. Biol Psychiatry. 2005; 58(5):424428.
135.Grant, P, Lougee, L, Hirschtritt, M, Swedo, SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007;17(6):761767.
136.Pittenger, C, Kelmendi, B, Wasylink, S, Bloch, MH, Coric, V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol. 2008;28(3):363367. Available from: doi:10.1097/JCP.0b013e3181727548 (accessed April 19, 2017).
137.Sasso, DA, Kalanithi, PS, Trueblood, KV, et al. Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors. J Clin Psychopharmacol. 2006;26(6):685687.
138.Pittenger, C. Glutamatergic agents for OCD and related disorders. Curr Treat Options Psychiatry. 2015;2(3):271283.
139.Berlin, HA, Koran, LM, Jenike, MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716721.
140.Afshar, H, Akuchekian, S, Mahaky, B, Zarean, E. Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(10):976981. Available from: (accessed April 19, 2017).
141.Kemp, DE, Gilmer, WS, Fleck, J, Dago, PL. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectr. 2007;12(2):106111.
142.Kuloglu, M, Caykoylu, A, Ekinci, O, Yilmaz, E. Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report. J Psychopharmacol. 2009;23(8):10011003.
143.Ozkara, C, Ozmen, M, Erdogan, A, Yalug, I. Topiramate related obsessive-compulsive disorder. Eur Psychiatry. 2005;20(1):7879.
144.Thuile, J, Even, C, Guelfi, JD. Topiramate may induce obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2006;60(3):394.
145.Kreek, MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186216.
146.Srisurapanont, M, Jarusuraisin, N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8(2):267280.
147.Lee, YK, Park, SW, Kim, YK, et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol. 2005;40(4):297301.
148.Kim, SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;59(4):159164.
149.Kim, SW, Grant, JE, Adson, DE, Shin, YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914921.
150.Grant, JE, Kim, SW. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann Clin Psychiatry. 2001;13(4):229231.
151.Grant, JE, Kim, SW. An open-label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry. 2002;63(4):349356.
152.Sandyk, R. Naloxone abolishes obsessive-compulsive behavior in Tourette’s syndrome. Int J Neurosci. 1987;35(1–2):9394.
153.Keuler, DJ, Altemus, M, Michelson, D, Greenberg, B, Murphy, DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry. 1996;40(2):154156.
154.Insel, TR, Pickar, D. Naloxone administration in obsessive compulsive disorder: report of two cases. Am J Psychiatry. 1983;140(9):12191220.
155.Amiaz, R, Fostick, L, Gershon, A, Zohar, J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008;18(6):455461.
156.Shapira, NA, Keck, PE Jr, Goldsmith, TD, McConville, BJ, Eis, M, McElroy, SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997;6(4):170173.
157.Hewlett, WA, Schmid, SP, Salomon, RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64(9):10251030.
158.Pallanti, S, Bernardi, S, Antonini, S, Singh, N, Hollander, E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014;24(3):375380.
159. Toren, P, Weizman, A, Ratner, S, Cohen, D, Laor, N. Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(4):499503.
160.Transcept Pharmaceuticals. Efficacy and safety study of low-dose ondansetron for adjunctive therapy in adult patients with obsessive-compulsive disorder. NCT01275248; 2011. Available from: (accessed July 13, 2018).
161.Koran, LM, Aboujaoude, E, Gamel, NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(11):15301535.
162.Perugi, G, Giannotti, D, Di Vaio, S, Frare, F, Saettoni, M, Cassano, GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphobia). Int Clin Psychopharmacol. 1996;11(4):247254.
163.Phillips, KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21(3):177179.
164.Phillips, KA, Dwight, MM, McElroy, SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165171.
165.Phillips, KA, Najjar, F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715720.
166.Phillips, KA, Albertini, RS, Rasmussen, SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381388.
167.Phillips, KA, Keshaviah, A, Dougherty, DD, Stout, RL, Menard, W, Wilhelm, S. Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. Am J Psychiatry. 2016;173(9):887895.
168.Rashid, H, Khan, AA, Fineberg, NA. Adjunctive antipsychotic in the treatment of body dysmorphic disorder – a retrospective naturalistic case note study. Int J Psychiatry Clin Practice. 2015;19(2):8489.
169.Hollander, E, Allen, A, Kwon, J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):10331039.
170.Ipser, JC, Sander, C, Stein, DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009;1:CD005473.
171.National Institute for Health and Care Excellence. Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder. Clinical Guideline CG31. London: NICE; 2006.
172.Phillips, KA, Albertini, RS, Siniscalchi, JM, Khan, A, Robinson, M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001;62(9):721727.
173.Phillips, KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(2):377379.
174.Uzun, Ӧ, Ӧzdemir, B. Aripriprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clin Drug Investig. 2010;30(10):707710.
175.Morein-Zamir, S, Papmeyer, M, Pertusa, A, et al. The profile of executive function in OCD hoarders and hoarding disorder. Psychiatry Res. 2014;215(3):659667.
176.Saxena, S. Pharmocotherapy of compulsive hoarding. J Clin Psychol. 2011;67(5):477484.
177.Saxena, S, Brody, AL, Maidment, KM, Baxter, LR Jr. Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 2007;41(6):481487.
178.Denys, D, van Megen, HJ, van der Wee, N, Westenberg, HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004;65(1):3743.
179.Denys, D, Van Nieuwerburgh, F, Deforce, D, Westenberg, HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68(5):747753.
180.Saxena, S, Sumner, J. Venlafaxine extended-release treatment of hoarding disorder. Int Clin Psychopharmacol. 2014;29(5):266273.
181.Bogan, AM, Koran, LM, Chuong, HW, Vapnik, T, Bystritsky, A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry. 2005;66(1):7379.
182.Rodriguez, CI, Bender, J Jr, Morrison, S, Mehendru, R, Tolin, D, Simpson, HB. Does extended release methylphenidate help adults with hoarding disorder?: a case series. J Clin Psychopharmacol. 2013;33(3):444447.
183.Swedo, SE, Leonard, HL, Rapoport, JL, Lenane, MC, Goldberger, EL, Cheslow, DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989;321(8):497501.
184.Swedo, SE, Lenane, MC, Leonard, HL. Long-term treatment of trichotillomania (hair pulling). N Engl J Med. 1993;329(2):141142.
185.Gadde, KM, Ryan Wagner, H 2nd, Connor, KM, Foust, MS. Escitalopram treatment of trichotillomania. Int Clin Psychopharmacol. 2007;22(1):3942.
186.Koran, LM, Ringold, A, Hewlett, W. Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull. 1992;28(2):145149.
187.Stein, DJ, Bouwer, C, Maud, CM. Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania. Eur Arch Psychiatry Clin Neurosci. 1997;247(4):234236.
188.Christenson, GA, Mackenzie, TB, Mitchell, JE, Callies, AL. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry. 1991;148(11):15661571.
189.Streichenwein, SM, Thornby, JI. A long-term, double-blind, placebo-controlled crossover trial. Am J Psychiatry. 1995;152(8):11921196.
190.Dougherty, DD, Loh, R, Jenike, MA, Keuthen, NJ. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry. 2006;67(7):10861092.
191.Rothbart, R, Amos, T, Siegfried, N, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2013;11:CD007662.
192.Pollard, CA, Ibe, IO, Krojanker, DN, Kitchen, AD, Bronson, SS, Flynn, TM. Clomipramine treatment of trichotillomania: a follow-up report on four cases. J Clin Psychiatry. 1991;52(3):128130.
193.Ninan, PT, Rothbaum, BO, Marsteller, FA, Knight, BT, Eccard, MB. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry. 2000;61(1):4750.
194.Van Ameringen, M, Mancini, C, Patterson, B, Bennett, M, Oakman, J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010;71(10):13361343.
195.White, MP, Koran, LM. Open-label trial of aripiprazole in the treatment of trichotillomania. J Clin Psychopharmacol. 2011;31(4):503506.
196.Stein, DJ, Hollander, E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry. 1992;53(4):123126.
197.De Sousa, A. An open-label pilot study of naltrexone in childhood-onset trichotillomania. J Child Adolesc Psychopharmacol. 2008;18(1):3033.
198.Grant, JE, Odlaug, BL, Schreiber, LR, Kim, SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(1):134138.
199.Grant, JE, Odlaug, BL, Kim, SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756763.
200.Bloch, MH, Panza, KE, Grant, JE, Pittenger, C, Leckman, JF. N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013;52(3):231240.
201.Panza, KE, Pittenger, C, Bloch, MH. Age and gender correlates of pulling in pediatric trichotillomania. J Am Acad Child Adolesc Psychiatry. 2013;52(3):241249.
202.Simeon, D, Stein, DJ, Gross, S, Islam, N, Schmeidler, J, Hollander, E. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry. 1997;58(8):341347.
203.Bloch, MR, Elliott, M, Thompson, H, Koran, LM. Fluoxetine in pathologic skin-picking: open-label and double-blind results. Psychosomatics. 2001;42(4):314319.
204.Arnold, LM, Mutasim, DF, Dwight, MM, Lamerson, CL, Morris, EM, McElroy, SL. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol. 1999;19(1):1518.
205.Keuthen, NJ, Jameson, M, Loh, R, Deckersbach, T, Wilhelm, S, Dougherty, DD. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol. 2007;22(5):268274.
206.Arbabi, M, Farnia, V, Balighi, K, et al. Efficacy of citalopram in treatment of pathological skin picking: a randomized double blind placebo controlled trial. Acta Medica Iranica. 2008;46(5):367372.
207.Grant, JE, Chamberlain, SR, Redden, SA, Leppink, EW, Odlaug, BL, Kim, SW. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):490496.
208.Morgan, JR, Storch, EA, Woods, DW, Bodzin, D, Lewin, AB, Murphy, TK. A preliminary analysis of the phenomenology of skin-picking in Prader-Willi syndrome. Child Psychiatry Hum Dev. 2010;41(4):448463.
209.Grant, JE, Odlaug, BL, Kim, SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry. 2007;68(9):13841391.
210.Grant, JE, Odlaug, BL, Chamberlain, SR, Kim, SW. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol. 2010;30(4):396403.
211.Benjamin, E, Buot-Smith, T. Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry. 1993;32(4):870873.
212.Brakoulias, V. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity. Expert Opin Pharmacother. 2014;15(10):13211323.
213.Phillips, KA, Hollander, E, Rasmussen, SA, Aronowitz, BR, Decaria, C, Goodman, WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997;33(1):1722.
214.Abramowitz, JS, Deacon, BJ, Olatunji, BO, et al. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol Assess. 2010;22(1):180198.
215.Keuthen, NJ, O’Sullivan, RL, Ricciardi, JN, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses. Psychother Psychosom. 1995;64(3–4):141145.
216.Tolin, DF, Frost, RO, Steketee, G. A brief interview for assessing compulsive hoarding: the Hoarding Rating Scale-Interview. Psychiatry Res. 2010;178(1):147152.
217.Foa, EB, Huppert, JD, Leiberg, S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol Assess. 2002;14(4):485496.
218.Winchel, RM, Jones, JS, Molcho, A, Parsons, B, Stanley, B, Stanley, M. The Psychiatric Institute Trichotillomania Scale (PITS). Psychopharmacol Bull. 1992;28(4):463476.
219.Frost, RO, Steketee, G, Grisham, J. Measurement of compulsive hoarding: saving inventory-revised. Behav Res Ther. 2004;42(10):11631182.
220.Keuthen, NJ, Wilhelm, S, Deckersbach, T, et al. The Skin Picking Scale: scale construction and psychometric analyses. J Psychosom Res. 2001;50(6):337341.
221.Stanley, MA, Breckenridge, JK, Snyder, AG, Novy, DM. Clinician-rated measures of hair pulling: a preliminary psychometric evaluation. J Psychopathol Behav Assess. 1999;21(2):157170.
222.Stanley, MA, Prather, RC, Wagner, AL, Davis, ML, Swann, AC. Can the Yale-Brown Obsessive Compulsive Scale be used to assess trichotillomania? A preliminary report. Behav Res Ther. 1993;31(2):171177.
223.Rosario-Campos, MC, Miguel, EC, Quatrano, S, et al. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry. 2006;11(5):495504.
224.LeBeau, RT, Mischel, ER, Simpson, HB, et al. Preliminary assessment of obsessive–compulsive spectrum disorder scales for DSM-5. J Obsessive-Compuls Relat Disord. 2013;2(2):114118.